This article has been updated with comments from company officials.

NEW YORK (GenomeWeb News) – Illumina today announced that it has acquired Cambridge, UK-based BlueGnome for an undisclosed sum.

The deal provides Illumina with BlueGnome's array-based cytogenetic and in vitro fertilization screening tests. The firm's 24sure test is a preimplantation genetic screening assay for counting the chromosomes in a single human cell and "holds enormous promise for increasing IVF success rates," said Illumina.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.